Daihan Pharmaceutical Co.,Ltd. (KOSDAQ: 023910)

Daihan Pharmaceutical Co.,Ltd. Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	201,974	195,911	184,268	171,463	166,080	168,762
Other Revenue	-	-	-	-0	-	-
Revenue	201,974	195,911	184,268	171,463	166,080	168,762
Revenue Growth (YoY)	3.83%	6.32%	7.47%	3.24%	-1.59%	6.33%
Cost of Revenue	133,952	130,599	124,455	115,781	109,885	109,565
Gross Profit	68,022	65,312	59,812	55,682	56,195	59,197
Selling, General & Admin	28,107	26,945	25,445	24,923	24,892	24,567
Research & Development	1,683	1,641	567.87	790.59	689.17	392.44
Other Operating Expenses	493.64	411.75	387.26	334.4	303.68	393.74
Operating Expenses	30,838	29,517	26,844	26,614	26,232	25,558
Operating Income	37,184	35,795	32,968	29,068	29,963	33,639
Interest Expense	-	-52.47	-593.43	-469.27	-617.06	-888.23
Interest & Investment Income	879.07	87.18	486.66	506.7	421.05	132.17
Currency Exchange Gain (Loss)	-124.13	504.71	525.35	687.03	-426.96	111.9
Other Non Operating Income (Expenses)	1,111	87.57	73.92	599.56	822.93	4,106
EBT Excluding Unusual Items	39,051	36,422	33,461	30,392	30,163	37,101
Gain (Loss) on Sale of Investments	342.34	288.69	-	-	-	-
Gain (Loss) on Sale of Assets	56.81	22.53	-9.4	41.28	19.72	29.98
Asset Writedown	-	-	-	-	-7,650	-
Pretax Income	39,450	36,734	33,451	30,433	22,532	37,131
Income Tax Expense	8,784	8,307	8,491	7,763	5,151	8,964
Net Income	30,665	28,426	24,961	22,670	17,381	28,167
Net Income to Common	30,665	28,426	24,961	22,670	17,381	28,167
Net Income Growth	17.00%	13.88%	10.10%	30.43%	-38.29%	-1.23%
Shares Outstanding (Basic)	6	6	6	6	6	6
Shares Outstanding (Diluted)	6	6	6	6	6	6
Shares Change (YoY)	-0.24%	-1.74%	-0.27%	0.02%	-0.02%	0.01%
EPS (Basic)	5215.14	4834.41	4171.00	3778.00	2897.00	4694.00
EPS (Diluted)	5215.14	4834.41	4171.00	3778.00	2897.00	4694.00
EPS Growth	17.28%	15.91%	10.40%	30.41%	-38.28%	-1.24%
Free Cash Flow	15,594	17,580	20,378	28,767	28,267	17,959
Free Cash Flow Per Share	2651.95	2989.79	3405.28	4794.06	4711.52	2992.84
Gross Margin	33.68%	33.34%	32.46%	32.47%	33.84%	35.08%
Operating Margin	18.41%	18.27%	17.89%	16.95%	18.04%	19.93%
Profit Margin	15.18%	14.51%	13.55%	13.22%	10.47%	16.69%
Free Cash Flow Margin	7.72%	8.97%	11.06%	16.78%	17.02%	10.64%
EBITDA	44,820	44,459	42,176	40,479	41,263	44,416
EBITDA Margin	22.19%	22.69%	22.89%	23.61%	24.85%	26.32%
D&A For EBITDA	7,635	8,663	9,208	11,411	11,300	10,777
EBIT	37,184	35,795	32,968	29,068	29,963	33,639
EBIT Margin	18.41%	18.27%	17.89%	16.95%	18.04%	19.93%
Effective Tax Rate	22.27%	22.61%	25.38%	25.51%	22.86%	24.14%
Advertising Expenses	-	78.69	93.67	63.18	48.89	86.68

Source: S&P Capital IQ. Standard template. Financial Sources.